UroGen Pharma (URGN) Misses Q3 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
Jefferies Assumes UroGen Pharma (URGN) at Buy
November 8, 2018 8:38 AM ESTJefferies analyst Chris Howerton assumes coverage on UroGen Pharma (NASDAQ: URGN) with a Buy rating and a price target of $77.00 (from $73.00).
The analyst assumes primary coverage from analyst Matthew Andrews.
For an analyst ratings summary and ratings history on UroGen... More



